Source link : https://www.newshealth.biz/health-news/alectinib-lands-fda-approval-for-adjuvant-therapy-in-nsclc/
The FDA extended indications for alectinib (Alecensa) to include adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first such approval for an ALK inhibitor. The approval stipulates use of alectinib as adjuvant therapy after surgery for tumors ≥4 cm or positive lymph nodes, as detected by an FDA-approved test. Principal support for the […]
Author : News Health
Publish date : 2024-04-19 17:16:24
Copyright for syndicated content belongs to the linked Source.